skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Explore Research Products in the PAR
It may take a few hours for recently added research products to appear in PAR search results.


Title: Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries
Abstract BackgroundThe emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control. This study aims to inform policymakers and vaccine developers on the potential of an effective malaria vaccine in reducing drug-resistant infections. MethodsA compartmental model estimating cases, drug-resistant cases, and deaths averted from 2021 to 2030 with a vaccine againstPlasmodium falciparuminfection administered yearly to 1-year-olds in 42 African countries. Three vaccine efficacy (VE) scenarios and one scenario of rapidly increasing drug resistance are modeled. ResultsWhen VE is constant at 40% for 4 years and then drops to 0%, 235.7 (Uncertainty Interval [UI] 187.8–305.9) cases per 1000 children, 0.6 (UI 0.4–1.0) resistant cases per 1000, and 0.6 (UI 0.5–0.9) deaths per 1000 are averted. When VE begins at 80% and drops 20 percentage points each year, 313.9 (UI 249.8–406.6) cases per 1000, 0.9 (UI 0.6–1.3) resistant cases per 1000, and 0.9 (UI 0.6–1.2) deaths per 1000 are averted. When VE remains 40% for 10 years, 384.7 (UI 311.7–496.5) cases per 1000, 1.0 (0.7–1.6) resistant cases per 1000, and 1.1 (UI 0.8–1.5) deaths per 1000 are averted. Assuming an effective vaccine and an increase in current levels of drug resistance to 80% by 2030, 10.4 (UI 7.3–15.8) resistant cases per 1000 children are averted. ConclusionsWidespread deployment of a malaria vaccine could substantially reduce health burden in Africa. Maintaining VE longer may be more impactful than a higher initial VE that falls rapidly.  more » « less
Award ID(s):
1918628
PAR ID:
10497755
Author(s) / Creator(s):
; ; ; ; ; ; ;
Publisher / Repository:
Communications Medicine volume
Date Published:
Journal Name:
Communications Medicine
Volume:
3
Issue:
1
ISSN:
2730-664X
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. ; ; ; ; ; ; ; ; (, PLOS Medicine)
    BackgroundDespite significant global progress in reducing neonatal mortality, bacterial sepsis remains a major cause of neonatal deaths.Klebsiella pneumoniae(K.pneumoniae) is the leading pathogen globally underlying cases of neonatal sepsis and is frequently resistant to antibiotic treatment regimens recommended by the World Health Organization (WHO), including first-line therapy with ampicillin and gentamicin, second-line therapy with amikacin and ceftazidime, and meropenem. Maternal vaccination to prevent neonatal infection could reduce the burden ofK.pneumoniaeneonatal sepsis in low- and middle-income countries (LMICs), but the potential impact of vaccination remains poorly quantified. We estimated the potential impact of such vaccination on cases and deaths ofK.pneumoniaeneonatal sepsis and project the global effects of routine immunization of pregnant women with theK.pneumoniaevaccine as antimicrobial resistance (AMR) increases. Methods and findingsWe developed a Bayesian mixture-modeling framework to estimate the effects of a hypotheticalK.pneumoniaematernal vaccine with 70% efficacy administered with coverage equivalent to that of the maternal tetanus vaccine on neonatal sepsis infections and mortality. To parameterize our model, we used data from 3 global studies of neonatal sepsis and/or mortality—with 2,330 neonates who died with sepsis surveilled from 2016 to 2020 undertaken in 18 mainly LMICs across all WHO regions (Ethiopia, Kenya, Mali, Mozambique, Nigeria, Rwanda, Sierra Leone, South Africa, Uganda, Brazil, Italy, Greece, Pakistan, Bangladesh, India, Thailand, China, and Vietnam). Within these studies, 26.95% of fatal neonatal sepsis cases were culture-positive forK.pneumoniae. We analyzed 9,070K.pneumoniaegenomes from human isolates gathered globally from 2001 to 2020 to quantify the temporal rate of acquisition of AMR genes inK.pneumoniaeisolates to predict the future number of drug-resistant cases and deaths that could be averted by vaccination.Resistance rates to carbapenems are increasing most rapidly and 22.43% [95th percentile Bayesian credible interval (CrI): 5.24 to 41.42] of neonatal sepsis deaths are caused by meropenem-resistantK.pneumoniae. Globally, we estimate that maternal vaccination could avert 80,258 [CrI: 18,084 to 189,040] neonatal deaths and 399,015 [CrI: 334,523 to 485,442] neonatal sepsis cases yearly worldwide, accounting for more than 3.40% [CrI: 0.75 to 8.01] of all neonatal deaths. The largest relative benefits are in Africa (Sierra Leone, Mali, Niger) and South-East Asia (Bangladesh) where vaccination could avert over 6% of all neonatal deaths. Nevertheless, our modeling only considers country-level trends inK.pneumoniaeneonatal sepsis deaths and is unable to consider within-country variability in bacterial prevalence that may impact the projected burden of sepsis. ConclusionsAK.pneumoniaematernal vaccine could have widespread, sustained global benefits as AMR inK.pneumoniaecontinues to increase. 
    more » « less
  2. ; ; (, Infectious Disease Modelling)
    A study in Burkina Faso revealed ivermectin inhibits malaria transmission by killing malaria parasites and mosquitoes. However, it is unknown what effect this drug will have on the malaria transmission intensities of the rest of sub-Saharan Africa (SSA). To address this issue, we created a mathematical model using malaria transmission data from 41 SSA countries to evaluate the antimalarial benefits of a mass drug administration (MDA) of ivermectin. To account for ivermectin's effect on malaria, we incorporate estimates of its ability to inhibit malaria transmission and kill mosquitoes. We consider scenarios where 0, 12.5 %, 25.0 %, and 50.0 % of the population receive ivermectin over five years and estimate malaria incidence averted, disability-adjusted life years saved, and the incremental cost-effectiveness ratio. Our findings show that an MDA of ivermectin to 12.5 %, 25 %, or 50 % of the population annually averts 248.7, 261.4, and 288.7 incidences per thousand people and saves 5.4, 5.7, and 6.3 disability-adjusted life years, respectively. These values indicate that an MDA of ivermectin would be cost-effective in 41, 18, and 6 countries, and very cost-effective in 22, 6, and 3 countries for the 12.5 %, 25 %, and 50 % scenarios. Altogether, our results indicate that ivermectin would prevent a substantial number of malaria incidences and save disability-adjusted life years in the majority of SSA. Therefore, an MDA of ivermectin would greatly aid in ongoing malaria control efforts and should be considered strongly as a complementary intervention to current malaria protocols. 
    more » « less
  3. ; ; ; ; ; ; ; ; (, Proceedings of the National Academy of Sciences)
    Tuberculosis (TB) is the world’s deadliest infectious disease, with over 1.5 million deaths and 10 million new cases reported anually. The causative organismMycobacterium tuberculosis(Mtb) can take nearly 40 d to culture, a required step to determine the pathogen’s antibiotic susceptibility. Both rapid identification and rapid antibiotic susceptibility testing of Mtb are essential for effective patient treatment and combating antimicrobial resistance. Here, we demonstrate a rapid, culture-free, and antibiotic incubation-free drug susceptibility test for TB using Raman spectroscopy and machine learning. We collect few-to-single-cell Raman spectra from over 25,000 cells of the Mtb complex strain Bacillus Calmette-Guérin (BCG) resistant to one of the four mainstay anti-TB drugs, isoniazid, rifampicin, moxifloxacin, and amikacin, as well as a pan-susceptible wildtype strain. By training a neural network on this data, we classify the antibiotic resistance profile of each strain, both on dried samples and on patient sputum samples. On dried samples, we achieve >98% resistant versus susceptible classification accuracy across all five BCG strains. In patient sputum samples, we achieve ~79% average classification accuracy. We develop a feature recognition algorithm in order to verify that our machine learning model is using biologically relevant spectral features to assess the resistance profiles of our mycobacterial strains. Finally, we demonstrate how this approach can be deployed in resource-limited settings by developing a low-cost, portable Raman microscope that costs <$5,000. We show how this instrument and our machine learning model enable combined microscopy and spectroscopy for accurate few-to-single-cell drug susceptibility testing of BCG. 
    more » « less
  4. ; ; ; ; ; ; ; ; ; ; et al (, IEEE International Conference on Big Data)
    We study the role of vaccine acceptance in controlling the spread of COVID-19 in the US using AI-driven agent-based models. Our study uses a 288 million node social contact network spanning all 50 US states plus Washington DC, comprised of 3300 counties, with 12.59 billion daily interactions. The highly-resolved agent-based models use realistic information about disease progression, vaccine uptake, production schedules, acceptance trends, prevalence, and social distancing guidelines. Developing a national model at this resolution that is driven by realistic data requires a complex scalable workflow, model calibration, simulation, and analytics components. Our workflow optimizes the total execution time and helps in improving overall human productivity.This work develops a pipeline that can execute US-scale models and associated workflows that typically present significant big data challenges. Our results show that, when compared to faster and accelerating vaccinations, slower vaccination rates due to vaccine hesitancy cause averted infections to drop from 6.7M to 4.5M, and averted total deaths to drop from 39.4K to 28.2K nationwide. This occurs despite the fact that the final vaccine coverage is the same in both scenarios. Improving vaccine acceptance by 10% in all states increases averted infections from 4.5M to 4.7M (a 4.4% improvement) and total deaths from 28.2K to 29.9K (a 6% increase) nationwide. The analysis also reveals interesting spatio-temporal differences in COVID-19 dynamics as a result of vaccine acceptance. To our knowledge, this is the first national-scale analysis of the effect of vaccine acceptance on the spread of COVID-19, using detailed and realistic agent-based models. 
    more » « less
  5. ; ; ; (, Current Clinical Microbiology Reports)
    Abstract Purpose of the ReviewSARS-CoV-2 undergoes genetic mutations like many other viruses. Some mutations lead to the emergence of new Variants of Concern (VOCs), affecting transmissibility, illness severity, and the effectiveness of antiviral drugs. Continuous monitoring and research are crucial to comprehend variant behavior and develop effective response strategies, including identifying mutations that may affect current drug therapies. Recent FindingsAntiviral therapies such as Nirmatrelvir and Ensitrelvir focus on inhibiting 3CLpro, whereas Remdesivir, Favipiravir, and Molnupiravir target nsp12, thereby reducing the viral load. However, the emergence of resistant mutations in 3CLpro and nsp12 could impact the efficiency of these small molecule drug therapeutics. SummaryThis manuscript summarizes mutations in 3CLpro and nsp12, which could potentially reduce the efficacy of drugs. Additionally, it encapsulates recent advancements in small molecule antivirals targeting SARS-CoV-2 viral proteins, including their potential for developing resistance against emerging variants. 
    more » « less
  • Citation Formats
  • MLA
  • APA
  • Chicago
  • BibTeX
  • Save / Share this Record
  • Send to Email